CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
Public ClinicalTrials.gov record NCT04575038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.
Study identification
- NCT ID
- NCT04575038
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2020 (Actual)
- Primary completion
- Apr 28, 2021 (Actual)
- Completion
- Apr 28, 2021 (Actual)
- Last update posted
- Apr 19, 2022
2020 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Homewood | Alabama | 35209 | — |
| Ark Clinical Research | Long Beach | California | 90806 | — |
| Doral Medical Research | Doral | Florida | 33166 | — |
| South Jersey Infectious Disease | Somers Point | New Jersey | 08244 | — |
| Monroe Biomedical Research | Monroe | North Carolina | 28112 | — |
| Wilmington Health | Wilmington | North Carolina | 28401 | — |
| Remington-Davis, Inc. | Columbus | Ohio | 43215 | — |
| Toledo Institute of Clinical Research | Toledo | Ohio | 43617 | — |
| VitaLink - Gaffney | Gaffney | South Carolina | 29615 | — |
| Self Regional Healthcare Research Center - Self Medical Group | Greenwood | South Carolina | 29646 | — |
| VitaLink Research | Spartanburg | South Carolina | 29303 | — |
| Clinical Trials Center of Middle Tennessee | Franklin | Tennessee | 37067 | — |
| Centex Studies, Inc. - McAllen | McAllen | Texas | 78504 | — |
| Synexus Clinical Research US, Inc. - Olympus Family Medicine | Salt Lake City | Utah | 84117 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04575038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04575038 live on ClinicalTrials.gov.